NEFL and Parkinson disease: Thus, as already proven for multiple sclerosis, Alzheimer, and Parkinson disease [70,71], the persistence of high plasma NfL levels in patients with COVID-19 during the post-acute phase of the disease could represent a biomarker of neurocognitive impairment.